|
|
Cell-of-Origin (COO) Classification, BCL2 and MYC Expression Associated Outcome in Younger Patients Treated By RCHOP Front-Line Therapy Versus Intensive Regimen Followed By Autologous Transplant for De Novo Advanced Diffuse Large B Cell Lymphoma (DLBCL) : Results of the French Prospective Multicenter Randomized Trial Goelams-075
Gaëlle Laboure
,
Marie-Cecile Parrens
,
Anjarasoa Tsaranazy
,
Magali Bordier
,
Steven Le Gouill
et al.
55th Annual Meeting and Exposition of the American-Society-of-Hematology, Dec 2013, La Nouvelle Orléans, United States. 126 (23), pp.3920, 2015
Conference poster
hal-01290432v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
18 F-Fludarabine PET for Lymphoma Imaging: First-in-Humans Study on DLBCL and CLL Patients
Sylvain Chantepie
,
Narinée Hovhannisyan
,
Stéphane Guillouet
,
Jean-Pierre J.-P. Pelage
,
Méziane Ibazizene
et al.
Journal articles
hal-02006592v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies.
Gandhi Damaj
,
Alain Duhamel
,
Marie Robin
,
Yves Beguin
,
Mauricette Michallet
et al.
Journal articles
inserm-00821506v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
Gandhi Damaj
,
Rémy Gressin
,
Krimo Bouabdallah
,
Guillaume Cartron
,
Bachra Choufi
et al.
Journal articles
inserm-00868869v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|